STAT3 and prostate cancer: Using the STAT3 small molecule inhibitor, Stattic, which has been shown to selectively inhibit the function of the STAT3 SH2 domain regardless of STAT3 phosphorylation status [30], we showed that Stattic potentially prevented phosphorylation of STAT3 in prostate cancer cells.